Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ford Motor Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Ford Motor Company trades at $13.95 (market cap $55.79B). The key difference: Ford Motor Company is the larger of the two by market cap, and Ford Motor Company pays a 4.29% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | F | |
|---|---|---|
Market Cap | $39.89B | $55.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $17.44 |
52-Week Low | $278.09 | $10.82 |
Enterprise Value | $38.15B | $184.81B |
Dividend Yield | — | 4.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Ford (F) trades at $13.995, up 2.83% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent developments include a tentative labor agreement in Canada and JD Power quality recognition, though vehicle recalls and declining EV sales present headwinds.
Ford's valuation appears attractive with low P/E and P/S ratios, but fundamental weakness in profitability and rising debt levels warrant caution. Analyst consensus leans neutral with $14.89 price target, while institutional sentiment shows divided opinions. The stock offers value potential if operational improvements materialize, but execution risks and competitive pressures remain significant concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
